Key Points
- Carl Dambkowski sold 5,500 shares on April 1 at an average price of $84.84 for $466,620 under a pre-arranged Rule 10b5-1 trading plan, leaving him with 208,398 shares (a 2.57% ownership decrease).
- The April sale continues a pattern of monthly disposals (Jan–Apr), totaling 35,200 shares sold year-to-date for roughly $2.67 million in proceeds, signalling sustained insider selling activity.
- Apogee trades near its one-year high with a market cap of about $5.86B; analysts carry a consensus rating of "Moderate Buy" and an average target of $110.79 despite negative EPS and a FY EPS forecast around -3.09.
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 5,500 shares of the firm's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $84.84, for a total transaction of $466,620.00. Following the sale, the insider owned 208,398 shares in the company, valued at approximately $17,680,486.32. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Carl Dambkowski also recently made the following trade(s):
- On Wednesday, March 4th, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The stock was sold at an average price of $71.06, for a total transaction of $390,830.00.
- On Wednesday, February 4th, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The stock was sold at an average price of $65.79, for a total value of $361,845.00.
- On Wednesday, January 7th, Carl Dambkowski sold 18,700 shares of Apogee Therapeutics stock. The shares were sold at an average price of $77.84, for a total value of $1,455,608.00.
Apogee Therapeutics Price Performance
Shares of Apogee Therapeutics stock opened at $84.34 on Friday. The firm has a market cap of $5.86 billion, a price-to-earnings ratio of -19.99 and a beta of 1.02. The stock's 50-day moving average is $71.40 and its 200-day moving average is $66.01. Apogee Therapeutics Inc. has a one year low of $26.20 and a one year high of $85.94.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.05) by $0.02. On average, equities analysts expect that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.
Analyst Ratings Changes
A number of analysts have recently commented on the stock. Mizuho boosted their price objective on shares of Apogee Therapeutics from $105.00 to $110.00 and gave the stock an "outperform" rating in a research report on Monday, March 30th. Craig Hallum reaffirmed a "buy" rating and issued a $116.00 target price on shares of Apogee Therapeutics in a research report on Wednesday, January 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Apogee Therapeutics in a research note on Wednesday, January 21st. Jefferies Financial Group reissued a "buy" rating and set a $95.00 price target on shares of Apogee Therapeutics in a research report on Monday, February 2nd. Finally, Stephens began coverage on Apogee Therapeutics in a report on Tuesday, December 16th. They issued an "overweight" rating and a $95.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $110.79.
Check Out Our Latest Research Report on APGE
Hedge Funds Weigh In On Apogee Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Apogee Therapeutics by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company's stock worth $921,000 after acquiring an additional 694 shares in the last quarter. Millennium Management LLC grew its position in shares of Apogee Therapeutics by 100.0% in the 1st quarter. Millennium Management LLC now owns 260,335 shares of the company's stock valued at $9,726,000 after acquiring an additional 130,164 shares during the period. Creative Planning acquired a new position in shares of Apogee Therapeutics during the 2nd quarter worth about $392,000. Legal & General Group Plc increased its stake in shares of Apogee Therapeutics by 7.4% during the 2nd quarter. Legal & General Group Plc now owns 27,689 shares of the company's stock worth $1,203,000 after purchasing an additional 1,907 shares during the last quarter. Finally, Prudential Financial Inc. raised its holdings in shares of Apogee Therapeutics by 176.4% in the 2nd quarter. Prudential Financial Inc. now owns 68,845 shares of the company's stock valued at $2,990,000 after purchasing an additional 43,940 shares during the period. 79.04% of the stock is owned by institutional investors.
About Apogee Therapeutics
(
Get Free Report)
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
